Prospects for human papillomavirus vaccine development: Emerging HPV vaccines

被引：21

作者：

Hines, JF ^{[1
]}

Ghim, S ^{[1
]}

Jenson, AB ^{[1
]}

机构：

[1] Brooke Army Med Ctr, Dept Obstet & Gynecol MCHE OG, Div Gynecol Oncol, Ft Sam Houston, TX 78234 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 1998年 / 10卷 / 01期

关键词：

D O I：

10.1097/00001703-199802000-00004

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

This review concentrates on recent advances in human papillomavirus vaccine development. Strategies for prophylactic HPV subunit vaccines utilizing recombinantly synthesized, immunogenic virus-like particles are discussed. Therapeutic strategies focusing on the induction of cell-mediated immunity and gene manipulation for the treatment of established HPV-associated disease are also reviewed. 1040-872X (C) 1998 Rapid Science Publishers.

引用

页码：15 / 19

页数：5

共 32 条

[1] Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope [J].

Alexander, M ;

Salgaller, ML ;

Celis, E ;

Sette, A ;

Barnes, WA ;

Rosenberg, SA ;

Steller, MA .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (06) :1586-1593

[2] Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells [J].

BeerRomero, P ;

Glass, S ;

Rolfe, M .

ONCOGENE, 1997, 14 (05) :595-602

[3] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [J].

Borysiewicz, LK ;

Fiander, A ;

Nimako, M ;

Man, S ;

Wilkinson, GWG ;

Westmoreland, D ;

Evans, AS ;

Adams, M ;

Stacey, SN ;

Boursnell, MEG ;

Rutherford, E ;

Hickling, JK ;

Inglis, SC .

LANCET, 1996, 347 (9014) :1523-1527

[4] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[5] Construction and characterisation of a recombinant vaccinia was expressing human papillomavirus proteins for immunotherapy of cervical cancer [J].

Boursnell, MEG ;

Rutherford, E ;

Hickling, JK ;

Rollinson, EA ;

Munro, AJ ;

Rolley, N ;

McLean, CS ;

Borysiewicz, LK ;

Vousden, K ;

Inglis, SC .

VACCINE, 1996, 14 (16) :1485-1494

[6] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION [J].

BREITBURD, F ;

KIRNBAUER, R ;

HUBBERT, NL ;

NONNENMACHER, B ;

TRINDINHDESMARQUET, C ;

ORTH, G ;

SCHILLER, JT ;

LOWY, DR .

JOURNAL OF VIROLOGY, 1995, 69 (06) :3959-3963

[7]

BROKER TR, 1987, OBSTET GYN CLIN N AM, V14, P329

[8]

DIMAIO D, 1991, ADV CANCER RES, V56, P133

[9] Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles [J].

Dupuy, C ;

BuzoniGatel, D ;

Touze, A ;

LeCann, P ;

Bout, D ;

Coursaget, P .

MICROBIAL PATHOGENESIS, 1997, 22 (04) :219-225

[10] VACCINATION WITH CYTOTOXIC T-LYMPHOCYTE EPITOPE-CONTAINING PEPTIDE PROTECTS AGAINST A TUMOR-INDUCED BY HUMAN PAPILLOMAVIRUS TYPE-16-TRANSFORMED CELLS [J].

FELTKAMP, MCW ;

SMITS, HL ;

VIERBOOM, MPM ;

MINNAAR, RP ;

DEJONGH, BM ;

DRIJFHOUT, JW ;

TERSCHEGGET, J ;

MELIEF, CJM ;

KAST, WM .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) :2242-2249

← 1 2 3 4 →